RB1 (Ab-807) Antibody

What is the biological significance of RB1 phosphorylation at Serine 807?

RB1 phosphorylation at Serine 807 serves as a key regulatory mechanism in the cell cycle, particularly at the G0-G1 transition. The retinoblastoma protein functions as a tumor suppressor and master regulator of cell division by controlling the G1/S transition . In its hypophosphorylated state, RB1 binds to transcription factors of the E2F family, preventing the transcription of E2F-responsive genes that are necessary for cell cycle progression . Phosphorylation of RB1 at specific residues, including Ser807, induces its dissociation from E2Fs, thereby activating transcription of E2F-responsive genes and triggering entry into S phase . Specifically, CDK3/cyclin-C-mediated phosphorylation at Ser-807 and Ser-811 is required for the G0-G1 transition . This phosphorylation event therefore represents a critical checkpoint in cell cycle control, with implications for both normal development and cancer biology.

How does RB1 S807 phosphorylation differ from other RB1 phosphorylation sites?

RB1 contains multiple phosphorylation sites that work in concert to regulate its activity. While Ser807/811 phosphorylation is specifically required for G0-G1 transition, other sites serve different functions in the regulation of RB1 activity:

The distinct pattern of phosphorylation across these sites creates a phosphorylation code that determines RB1 activity status . Unlike some other sites, S807 phosphorylation appears early in the cell cycle reactivation process, making it a valuable marker for cells exiting quiescence .

Which RB1 (Ab-807) antibodies are most widely validated for research applications?

Several well-validated antibodies targeting RB1 phosphorylated at Ser807 are available for research, each with specific validation profiles:

These antibodies have undergone rigorous validation including western blot analysis with phospho-peptide blocking controls, immunohistochemistry on various tissues, and citation in peer-reviewed publications .

What are the optimal sample preparation methods for detecting phospho-RB1 (S807) in different experimental contexts?

The detection of phosphorylated RB1 requires careful sample preparation to preserve phosphorylation status:

For Western Blot:

• Rapidly harvest cells and immediately lyse in buffer containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate)

• For nuclear proteins like RB1, use nucleus extraction kits (e.g., Minute™ Cytoplasmic and Nuclear Fractionation kit as used in validation studies)

• Maintain samples at 4°C throughout processing and avoid repeated freeze-thaw cycles

• Include positive controls (e.g., serum-stimulated K562 cells) which show increased phosphorylation

For Immunohistochemistry:

• Use heat-mediated antigen retrieval in EDTA buffer (pH 8.0) for paraffin-embedded sections

• Block with 10% goat serum to reduce background

• For frozen sections, fix with paraformaldehyde and permeabilize with 0.1% Triton X-100

• Consider phospho-peptide blocking controls to confirm specificity

For Immunofluorescence:

• Fix cells with PFA and permeabilize with 0.1% Triton X-100

• Block in 10% serum for 45 minutes at 25°C

• Use secondary antibodies conjugated to appropriate fluorophores (e.g., Alexa Fluor 594)

How should researchers troubleshoot weak or inconsistent phospho-RB1 (S807) signal in Western blots?

When encountering weak or inconsistent phospho-RB1 (S807) signals, consider the following troubleshooting steps:

• Phosphorylation preservation issues:

  • Ensure rapid sample processing with fresh phosphatase inhibitors

  • Check if cells were harvested at appropriate cell cycle stage (phosphorylation is cell cycle-dependent)

  • Consider treating samples with phosphatase inhibitors like calyculin A prior to lysis

• Antibody specificity concerns:

  • Run a phospho-peptide blocking control in parallel; signal should disappear with specific blocking peptide

  • Test antibody on known positive controls (e.g., K562 cells treated with 10% serum)

  • Verify molecular weight (RB1 should appear at ~110 kDa)

• Technical optimization:

  • Adjust antibody dilution (try 1:500-1:2000 range for most phospho-RB1 antibodies)

  • Optimize protein loading (30-50 μg total protein typically required)

  • Extend primary antibody incubation time (overnight at 4°C often yields best results)

  • Use high-sensitivity ECL detection systems for weakly phosphorylated samples

• Cell cycle considerations:

  • Synchronize cells to enrich for G0/G1 or G1/S transitions when phosphorylation occurs

  • Compare with total RB1 antibody to determine if the issue is with protein expression or phosphorylation

What controls should be included when studying RB1 phosphorylation dynamics?

A comprehensive experimental design should include the following controls:

• Positive and negative phosphorylation controls:

  • Positive: Serum-stimulated cells (10% serum treatment of K562 cells)

  • Negative: Serum-starved cells or cells treated with CDK inhibitors

  • Phospho-peptide blocking control to confirm antibody specificity

• Comparative phosphorylation controls:

  • Total RB1 antibody to normalize phosphorylation signals

  • Antibodies against other RB1 phosphorylation sites (e.g., S780, T821) to assess phosphorylation patterns

  • Time-course analysis to track phosphorylation dynamics during cell cycle progression

• Genetic controls:

  • RB1 knockout or knockdown cells (e.g., using Pax7CreER,Rb1 conditional knockout model)

  • Phospho-site mutants (S807A) to confirm signal specificity

  • Cells expressing constitutively active CDK3 to increase S807 phosphorylation

• Additional verification approaches:

  • Use multiple antibodies targeting the same phospho-site from different vendors

  • Consider mass spectrometry-based phospho-proteomic analysis for absolute confirmation

  • Include loading controls appropriate for nuclear proteins (e.g., Lamin B1)

How can phospho-RB1 (S807) antibodies be used to investigate cell cycle regulation in cancer models?

Phospho-RB1 (S807) antibodies offer powerful tools for investigating dysregulated cell cycle control in cancer through several sophisticated approaches:

• Cancer cell line screening and patient sample analysis:

  • Compare phosphorylation patterns across cancer cell lines and patient-derived xenografts

  • Correlate phosphorylation status with CDK inhibitor sensitivity in preclinical models

  • Perform immunohistochemical analysis of tumor tissue microarrays to establish clinical correlations

• Mechanistic studies of RB1 inactivation:

  • Investigate how oncogenic pathways alter S807 phosphorylation dynamics

  • Study how viral oncoproteins (SV40 large T antigen, HPV E7, adenovirus E1A) affect RB1 phosphorylation pattern

  • Assess phosphorylation changes in response to targeted therapies (e.g., CDK4/6 inhibitors)

• Multiparametric flow cytometry applications:

  • Combine phospho-RB1 (S807) detection with DNA content analysis to precisely map phosphorylation events to cell cycle phases

  • Incorporate markers of proliferation (Ki67), DNA damage (γH2AX), and apoptosis (cleaved caspase-3)

  • Track rare cell populations within heterogeneous tumors

• Therapeutic response monitoring:

  • Monitor RB1 phosphorylation status as a pharmacodynamic biomarker during clinical trials

  • Evaluate changes in phosphorylation patterns following treatment with cytotoxic versus cytostatic agents

  • Correlate with patient outcome to identify predictive signatures

What are the most reliable approaches for quantifying changes in RB1 S807 phosphorylation?

Accurate quantification of RB1 S807 phosphorylation requires robust analytical approaches:

• Western blot quantification strategies:

  • Use infrared fluorescence-based detection systems (e.g., LI-COR Odyssey) for broader linear dynamic range

  • Always normalize phospho-signal to total RB1 protein levels

  • Include standard curves with recombinant phosphorylated and non-phosphorylated proteins

  • Apply appropriate statistical analyses for replicate experiments

• Image-based quantification methods:

  • For IHC/IF samples, use automated image analysis algorithms to quantify nuclear signal intensity

  • Establish clear thresholds for positive versus negative staining

  • Generate H-scores (intensity × percentage of positive cells) for semi-quantitative analysis

  • Consider multiplex immunofluorescence to analyze multiple parameters simultaneously

• Flow cytometry-based approaches:

  • Develop phospho-flow protocols with appropriate fixation and permeabilization buffers

  • Gate on cell cycle phases using DNA content staining

  • Calculate median fluorescence intensity (MFI) and phosphorylation index relative to controls

  • Perform single-cell analysis to detect subpopulations with distinct phosphorylation states

• Emerging quantitative techniques:

  • Consider mass cytometry (CyTOF) for high-dimensional analysis with minimal spectral overlap

  • Explore proximity ligation assays (PLA) to study interactions between phospho-RB1 and binding partners

  • Evaluate phospho-proteomic approaches for global phosphorylation pattern analysis

How does RB1 S807 phosphorylation interact with other post-translational modifications to create a functional "RB1 code"?

RB1 function is regulated by a complex interplay of post-translational modifications that form a functional "code":

• Hierarchical phosphorylation patterns:

  • S807/811 phosphorylation appears early in the modification cascade, potentially serving as a priming event

  • Monomethylation at Lys-810 by SMYD2 enhances phosphorylation at Ser-807 and Ser-811, promoting cell cycle progression

  • Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domain and Pocket domain, inhibiting E2F binding

• Cross-talk between modifications:

  Modification	Site	Effect on S807 Phosphorylation	Functional Outcome
  Methylation	K810	Enhanced	Promotes cell cycle progression
  Acetylation	K873/K874	Altered subcellular localization	Affects phosphorylation patterns
  Phosphorylation	S780	Cooperative	Synergistic effect on E2F release
  Dephosphorylation	S795	Associated with S807 dephosphorylation	Occurs upon calcium stimulation

• Context-dependent modification patterns:

  • In quiescent cells, RB1 is hypophosphorylated at multiple sites including S807

  • During G0-G1 transition, CDK3/cyclin-C initiates phosphorylation at S807/S811

  • Additional sites become phosphorylated during G1 progression by CDK4/6 and CDK2

  • Specific dephosphorylation events occur during cellular stress or differentiation

• Advanced techniques to study modification interplay:

  • Utilize antibodies recognizing dual modifications (e.g., methyl-K810/phospho-S807)

  • Apply mass spectrometry to map the combinatorial landscape of modifications

  • Generate RB1 constructs with mutation of specific sites to assess interdependence

What are the current limitations of phospho-RB1 (S807) antibodies in translational research?

Despite their utility, phospho-RB1 (S807) antibodies face several limitations that researchers should consider:

• Technical challenges:

  • Variable sensitivity across different tissue preparations and fixation methods

  • Limited capacity to distinguish between mono-phosphorylation (S807 only) and dual-phosphorylation (S807/S811)

  • Cross-reactivity concerns with highly homologous family members (p107, p130) in some systems

  • Potential epitope masking due to protein-protein interactions or other modifications

• Biological interpretation limitations:

  • Snapshot measurement fails to capture dynamic phosphorylation changes

  • Difficulty in distinguishing functional versus non-functional phosphorylation events

  • Challenge of correlating phosphorylation status with downstream functional outcomes

  • Heterogeneity within samples leading to ambiguous signals

• Standardization issues:

  • Lack of universally accepted positive and negative controls across studies

  • Inconsistent reporting of antibody validation methods in publications

  • Variability between antibody lots affecting reproducibility

  • Absence of standardized protocols for quantification across laboratories

• Translational research gaps:

  • Limited evaluation of phospho-RB1 as predictive biomarkers in large clinical cohorts

  • Insufficient integration with other cell cycle biomarkers in clinical decision-making

  • Need for improved methods to assess phosphorylation in limited clinical specimens

  • Challenges in developing companion diagnostics based on phosphorylation status

How can RB1 (S807) phosphorylation status be used to predict therapeutic response in cancer?

RB1 phosphorylation status has emerged as a potential predictive biomarker for therapeutic response:

• Differential responses based on RB1 status:

  • RB1 deficiency is associated with improved response to DNA-damaging agents in breast cancer models

  • RB1 pathway deregulation correlates with tamoxifen resistance in ER+ breast tumors

  • High RB1 expression correlates with poor prognosis in ovarian carcinoma patients following surgery and chemotherapy

  • Loss of RB1 expression is associated with improved response to radiation in bladder cancer

• Predictive potential of S807 phosphorylation specifically:

  • Hyperphosphorylation at S807/S811 indicates active CDK activity and potentially greater sensitivity to CDK inhibitors

  • The ratio of phospho-S807 to total RB1 may predict cell cycle state and proliferative potential

  • S807 phosphorylation patterns may identify tumors with intact versus compromised RB1 pathway function

  • Monitoring changes in S807 phosphorylation during treatment could serve as a pharmacodynamic marker

• Integration into precision medicine approaches:

  • Develop immunohistochemistry-based scoring systems for phospho-RB1 in clinical specimens

  • Combine with other cell cycle markers (cyclin D1, p16) for enhanced predictive power

  • Create multiparametric prediction models incorporating genomic and phosphoproteomic data

  • Establish cutoff values for "high" versus "low" phosphorylation with clinical relevance

• Emerging therapeutic implications:

  • Guide selection of patients for CDK4/6 inhibitor therapy in breast and other cancers

  • Inform combination strategies with conventional chemotherapy versus targeted agents

  • Direct sequencing of treatments based on dynamic changes in phosphorylation status

  • Develop synthetic lethal approaches exploiting RB1 phosphorylation state

What emerging methodologies might enhance phospho-RB1 (S807) detection in complex biological systems?

Several cutting-edge approaches show promise for advancing phospho-RB1 detection and analysis:

• Single-cell analysis technologies:

  • Single-cell Western blotting for heterogeneity assessment at the protein level

  • Mass cytometry (CyTOF) for high-dimensional analysis of phospho-epitopes

  • Single-cell phospho-proteomics to reveal cell-specific signaling networks

  • In situ sequencing methods to correlate phosphorylation with spatial context

• Live-cell biosensor development:

  • FRET-based sensors for real-time monitoring of RB1 phosphorylation dynamics

  • Split luciferase complementation assays to detect conformational changes upon phosphorylation

  • Phospho-specific intrabodies for tracking S807 phosphorylation in living cells

  • Optogenetic tools to induce phosphorylation with spatial and temporal precision

• Advanced imaging approaches:

  • Super-resolution microscopy to visualize phospho-RB1 nuclear distribution patterns

  • Expansion microscopy for enhanced spatial resolution of nuclear phospho-proteins

  • Correlative light and electron microscopy to link phosphorylation to ultrastructural features

  • Digital spatial profiling for multiplex analysis in tissue microenvironments

• Computational and systems biology integration:

  • Machine learning algorithms to identify subtle phosphorylation patterns

  • Mathematical modeling of phosphorylation dynamics in response to therapy

  • Network analysis to position S807 phosphorylation within broader signaling contexts

  • Development of predictive models integrating multiple post-translational modifications

What is the optimal protocol for phospho-RB1 (S807) detection by Western blot?

The following protocol has been optimized based on validated approaches from multiple sources:

Materials Required:

• Phospho-RB1 (S807) primary antibody

• Total RB1 antibody (for normalization)

• Phosphatase inhibitor cocktail (containing sodium fluoride, sodium orthovanadate)

• Protease inhibitor cocktail

• Nuclear extraction buffer or RIPA buffer with phosphatase inhibitors

• SDS-PAGE system (8% gel recommended for RB1's 110 kDa size)

Protocol:

• Sample preparation:

  • Harvest cells rapidly and wash with ice-cold PBS containing phosphatase inhibitors

  • For nuclear enrichment, use a nuclear extraction kit

  • Lyse cells in buffer containing both protease and phosphatase inhibitors

  • Determine protein concentration using Bradford or BCA assay

• SDS-PAGE and transfer:

  • Load 30-50 μg of protein per lane on 8% SDS-PAGE gel

  • Include positive control (serum-stimulated K562 cells)

  • Transfer to PVDF membrane (0.45 μm pore size) at 100V for 90 minutes or 30V overnight at 4°C

• Antibody incubation:

  • Block membrane in 5% BSA in TBST for 1 hour at room temperature

  • Incubate with phospho-RB1 (S807) antibody at 1:1000 dilution in 5% BSA/TBST overnight at 4°C

  • Wash 3×10 minutes with TBST

  • Incubate with HRP-conjugated secondary antibody at 1:5000 in 5% BSA/TBST for 1 hour at room temperature

• Detection and analysis:

  • Develop using ECL substrate and image using appropriate system

  • Strip and reprobe with total RB1 antibody for normalization

  • Quantify band intensities and calculate phospho-RB1/total RB1 ratio

  • For validation, run parallel blot with phospho-peptide blocking

How should researchers optimize immunohistochemistry protocols for phospho-RB1 (S807) detection in tissue samples?

Optimized IHC protocol for phospho-RB1 (S807) detection in paraffin-embedded tissues:

Materials Required:

• Phospho-RB1 (S807) antibody

• EDTA buffer (pH 8.0) for antigen retrieval

• Blocking serum (10% goat serum recommended)

• Detection system (e.g., HRP-conjugated secondary antibody)

• DAB chromogen

Protocol:

• Tissue preparation:

  • Section paraffin-embedded tissue at 4-5 μm thickness

  • Mount sections on positively charged slides

  • Deparaffinize in xylene and rehydrate through graded alcohols to water

• Antigen retrieval:

  • Perform heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

  • Heat in pressure cooker or microwave until boiling, then maintain at sub-boiling temperature for 20 minutes

  • Cool sections to room temperature (approximately 20 minutes)

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% hydrogen peroxide for 10 minutes

  • Wash in PBS, 3×5 minutes

  • Block with 10% goat serum for 30-60 minutes at room temperature

  • Apply primary antibody at optimal dilution (1:50-1:200 for most phospho-RB1 antibodies)

  • Incubate overnight at 4°C in humidified chamber

• Detection and counterstaining:

  • Wash 3×5 minutes in PBS

  • Apply HRP-conjugated secondary antibody and incubate for 30 minutes at 37°C

  • Wash 3×5 minutes in PBS

  • Develop with DAB for 5-10 minutes, monitoring for signal development

  • Counterstain with hematoxylin, dehydrate, clear, and mount

• Controls and optimization:

  • Include positive control tissue (human breast carcinoma recommended)

  • Run parallel section with phospho-peptide blocking to confirm specificity

  • Titrate antibody concentration to achieve optimal signal-to-noise ratio

  • Consider automated IHC platforms for consistent results across specimens

What is the recommended workflow for studying RB1 phosphorylation dynamics during cell cycle progression?

A comprehensive workflow for analyzing RB1 phosphorylation throughout the cell cycle:

Experimental Design:

• Cell synchronization methods:

  • Serum starvation (0.1% FBS for 24-48 hours) to enrich for G0/G1 phase

  • Thymidine double block for G1/S boundary synchronization

  • Nocodazole treatment for mitotic arrest

  • Contact inhibition followed by replating for synchronized cell cycle entry

• Time-course sample collection:

  • Collect samples at multiple timepoints after synchronization release

  • Critical timepoints: 0h (G0/G1), 6h (mid-G1), 12h (G1/S), 18h (S), 24h (G2/M)

  • Process samples immediately to preserve phosphorylation status

• Multi-parameter analysis workflow:

  • For each timepoint, split samples for parallel analyses:
    a) Flow cytometry for cell cycle distribution (propidium iodide staining)
    b) Western blotting for phospho-RB1 (S807) and total RB1
    c) Immunofluorescence for subcellular localization
    d) RT-qPCR for E2F target gene expression

• Data integration and visualization:

  • Plot phosphorylation levels against cell cycle distribution

  • Correlate S807 phosphorylation with expression of E2F target genes

  • Compare phosphorylation patterns across multiple RB1 sites (S807, S780, T821)

  • Generate integrated models of RB1 phosphorylation dynamics

• Perturbation analysis:

  • Treat synchronized cells with CDK inhibitors at different timepoints

  • Evaluate effects of phosphatase activators on RB1 dephosphorylation kinetics

  • Compare wild-type cells with RB1 phospho-site mutants

  • Assess the impact of oncogenic stressors on phosphorylation patterns

This comprehensive workflow enables detailed characterization of RB1 phosphorylation dynamics and their functional consequences throughout cell cycle progression.

How should researchers interpret discrepancies between phospho-RB1 (S807) antibody results from different vendors?

When faced with discrepancies between phospho-RB1 (S807) antibody results from different vendors, researchers should systematically evaluate:

• Antibody-specific factors:

  • Immunogen differences: Some antibodies are raised against S807 only, while others target dual phosphorylation at S807/S811

  • Clonality variations: Monoclonal antibodies provide higher specificity but may be more sensitive to epitope masking than polyclonal antibodies

  • Host species and production method: Recombinant antibodies may offer higher consistency than traditional hybridoma-derived antibodies

  • Lot-to-lot variation: Even within the same catalog number, performance can vary between manufacturing lots

• Experimental validation approaches:

  • Perform side-by-side testing using identical samples and protocols

  • Include phospho-peptide blocking controls for each antibody

  • Test on known positive (serum-stimulated) and negative (serum-starved) samples

  • Validate with genetic controls (RB1 knockout cells or phospho-site mutants)

• Technical considerations:

  • Buffer compatibility: Some antibodies perform optimally in specific blocking agents (BSA vs. milk)

  • Incubation conditions: Temperature and duration requirements may differ between antibodies

  • Detection system sensitivity: Enhanced chemiluminescence systems vary in sensitivity and dynamic range

  • Sample preparation: Effectiveness of phosphatase inhibitors and extraction protocols may affect results

• Resolution strategies:

  • Prioritize antibodies with published validation in your specific application and cell/tissue type

  • Consider using orthogonal methods to confirm phosphorylation status (e.g., mass spectrometry)

  • Report discrepancies to vendors and request additional validation data

  • When publishing, clearly document which antibody was used and include validation controls

What are the challenges in distinguishing between mono-phosphorylation (S807) and dual-phosphorylation (S807/S811) of RB1?

The close proximity of S807 and S811 presents several analytical challenges:

• Antibody specificity limitations:

  • Many commercial antibodies detect both mono (S807) and dual (S807/S811) phosphorylation

  • Antibody cross-reactivity between these sites is common due to similar surrounding sequences

  • Few antibodies have been rigorously validated for absolute specificity to one phosphorylation state

  • Phospho-peptide blocking may not distinguish between mono and dual phosphorylation

• Biological significance considerations:

  • Both sites are phosphorylated by similar kinases (CDK3/cyclin-C)

  • The sites often undergo coordinated phosphorylation during cell cycle progression

  • Functional differences between mono and dual phosphorylation remain incompletely characterized

  • Temporal ordering of phosphorylation events is difficult to establish with static measurements

• Advanced techniques for discrimination:

  • Phospho-specific mass spectrometry can definitively distinguish between phosphorylation states

  • Custom antibodies raised against dual-phosphorylated peptides with validation against mono-phosphorylated controls

  • Phosphatase treatment followed by in vitro kinase assays with site-specific kinases

  • Genetic models with S807A or S811A mutations to force mono-phosphorylation

• Experimental design recommendations:

  • Use multiple antibodies with different reported specificities

  • Include appropriate controls (phospho-null and phospho-mimetic mutants)

  • Consider in vitro dephosphorylation/rephosphorylation experiments

  • Acknowledge limitations in distinguishing these states when reporting results

How can researchers reconcile contradictory findings about the role of RB1 S807 phosphorylation in tumor suppression versus progression?

The seemingly contradictory roles of RB1 S807 phosphorylation reflect its context-dependent functions:

By carefully considering these factors, researchers can better understand and reconcile seemingly contradictory findings about RB1 S807 phosphorylation.

What are the key literature resources for understanding RB1 phosphorylation biology?

A curated list of seminal papers and reviews on RB1 phosphorylation:

Foundational Studies:

• Sherr, C.J. (1996) Science 274:1672-7 - Classic review on cell cycle control by RB1

• Knudsen, E.S. and Wang, J.Y. (1997) Mol Cell Biol 17:5771-83 - Established the role of RB1 phosphorylation in cell cycle control

• Lundberg, A.S. and Weinberg, R.A. (1998) Mol Cell Biol 18:753-61 - Demonstrated the sequential phosphorylation of RB1

• Kitagawa, M. et al. (1996) EMBO J 15:7060-9 - Identified specific kinases responsible for RB1 phosphorylation

• Geng, Y. et al. (2001) Proc Natl Acad Sci USA 98:194-9 - Showed requirement for cyclin D1 in RB1 phosphorylation

Comprehensive Reviews:

• Dick, F.A. & Rubin, S.M. (2013) Nat Rev Mol Cell Biol 14:297-311 - "Molecular mechanisms underlying RB protein function"

• Rubin, S.M. (2013) Protein Sci 22:1620-1632 - "Deciphering the retinoblastoma protein phosphorylation code"

• Dyson, N.J. (2016) Genes Dev 30:1492-1502 - "RB1: a prototype tumor suppressor and an enigma"

Advanced Topics:

• Sanidas, I. et al. (2019) Cell Rep 26:2651-2664 - "A code of mono-phosphorylation modulates the function of RB"

• Narasimha, A.M. et al. (2014) Elife 3:e02872 - "Cyclin D activates the Rb tumor suppressor by mono-phosphorylation"

• Chung, J. et al. (2019) Sci Signal 12:eaau7517 - "Phosphorylation by CDK1 induces Plk1-mediated disassembly of the RB complex"

What bioinformatic tools are available for analyzing RB1 phosphorylation sites and their conservation?

Researchers can leverage several computational resources for RB1 phosphorylation analysis:

• Phosphorylation site databases:

  • PhosphoSitePlus (phosphosite.org) - Comprehensive database of experimentally observed phosphorylation sites

  • UniProt (uniprot.org) - Curated protein information including post-translational modifications

  • PhosphoDB (phosphodb.org) - Database integrating phosphorylation data across species

  • PHOSIDA (phosida.org) - Phosphorylation site database with evolutionary conservation analysis

• Kinase prediction tools:

  • NetPhos - Neural network-based prediction of serine, threonine and tyrosine phosphorylation sites

  • GPS - Group-based Prediction System for kinase-specific phosphorylation site prediction

  • KinasePhos - Support vector machines for predicting kinase-specific phosphorylation sites

  • Scansite - Prediction of protein phosphorylation sites based on binding motifs

• Structural analysis tools:

  • PyMOL - Visualization of RB1 protein structure and phosphorylation sites

  • UCSF Chimera - Interactive visualization and analysis of molecular structures

  • I-TASSER - Protein structure prediction useful for regions lacking crystal structures

  • SWISS-MODEL - Automated protein homology-modeling server

• Conservation analysis resources:

  • Clustal Omega - Multiple sequence alignment to assess conservation across species

  • ConSurf - Evolutionary conservation analysis of protein sequences and structures

  • Jalview - Multiple sequence alignment viewer with conservation analysis

  • ESPript - Secondary structure-annotated sequence alignments

What are the recommended positive and negative control samples for phospho-RB1 (S807) antibody validation?

A comprehensive panel of controls for rigorous phospho-RB1 (S807) antibody validation:

Positive Controls:

• Cell line-based controls:

  • K562 cells treated with 10% serum (validated positive control)

  • MCF7 breast cancer cells stimulated with serum after starvation

  • HeLa cells in exponential growth phase

  • Primary fibroblasts stimulated to re-enter the cell cycle from quiescence

• Tissue-based controls:

  • Human breast carcinoma tissue (established positive control for IHC)

  • Mouse spleen tissue (validated for phospho-RB1 detection)

  • Highly proliferative tissues (embryonic, skin, intestinal crypts)

  • Tissue microarrays containing multiple positive control tissues

Negative Controls:

• Cell line-based controls:

  • Serum-starved cells (0.1% FBS for 24-48 hours)

  • Cells treated with CDK4/6 inhibitors (palbociclib, ribociclib)

  • RB1 knockout cells (e.g., SAOS-2 osteosarcoma cell line)

  • Cells expressing phospho-deficient RB1 mutant (S807A)

• Treatment-based controls:

  • Samples treated with lambda phosphatase

  • Cells arrested in late M-phase when RB1 is dephosphorylated

  • Contact-inhibited primary cells

  • Terminally differentiated tissues with minimal proliferation

Specificity Controls:

• Blocking controls:

  • Phospho-peptide competition (pre-incubation with phospho-S807 peptide)

  • Non-phosphorylated peptide competition (should not block signal)

  • Dual-phosphorylated (S807/S811) peptide blocking

• Technical controls:

  • Secondary antibody-only control

  • Isotype control antibody

  • Cross-reactivity testing with other phosphorylated RB family members (p107, p130)

  • Total RB1 antibody for comparison